Selexipag

Active substance Selexipag
Domain Lung diseases
Reason of inclusion in Horizonscan Geneesmiddelen New medicine (specialité)
Main indication Other lung
Extended indication Pulmonale arteriële hypertensie (PAH) WHO-klasse II–III bij volwassenen als monotherapie of als combinatietherapie met een endothelinereceptorantagonist (ERA) en/of een fosfodiësteraseremmer (PDE-5-remmer).

Product

Proprietary name Uptravi
Manufacturer Janssen
Mechanism of action Receptor agonist
Route of administration Intravenous
Additional comments selectieve prostacycline IP-receptoragonist.

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity New therapeutical formulation
Orphan drug Yes
Registration phase No registration expected
Additional comments Fabrikant geeft aan dat de intraveneuze vorm enkel in de Verenigde Staten op de markt zal komen. Op dit moment in tabletvorm goedgekeurd.

Therapeutic value

Current treatment options Keuze op basis van vasoreactiviteit, risicoprognose en aangetoonde werkzaamheid per middel, bijvoorbeeld: Endothelinereceptor-antagonisten, Guanylaatcyclase-stimulator, PDE-5-remmers, Prostacycline-analogen, Prostacycline IP-receptor-agonisten.
Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

Additional comments De geschatte prevalentie van PAH is 15-52 per 1.000.000.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.